

<i>Product Licence Number</i>	<i>Company Name</i>	<i>Product Name</i>	<i>Active Ingredients</i>	<i>Indications</i>	<i>Date of Authorisation</i>
00031/0341	Roche Products Limited	Roferon-A Vials, 4.5 Million International Units	Interferon Alfa 2a (rbe) HSE 4.5 MU	Prescription Only Medicine Same as in PL 00031/0340	25th November, 1994
00031/0342	Roche Products Limited	Roferon-A Vials, 9 Million International Units	Interferon Alfa 2a (rbe) HSE 9.0 MU	Prescription Only Medicine Same as in PL 00031/0340	25th November, 1994
00031/0343	Roche Products Limited	Roferon-A Vials, 18 Million International Units	Interferon Alfa 2a (rbe) HSE 18.0 MU	Prescription Only Medicine Same as in PL 00031/0340	25th November, 1994
00043/0191	Leo Laboratories Limited	Innohep® 5,000 anti-Factor Xa IU in 5 ml	Tinzaparin Sodium (Low molecular weight heparin) HSE 5,000 anti-factor Xa IU in 5 ml.	Prescription Only Medicine For the prevention of clotting in the extracorporeal circuit during haemodialysis in patients with chronic renal insufficiency.	22nd November, 1994
00057/0383	Pfizer Limited	Diffucan Capsules 50 mg	Fluconazole HSE 50.0 mg	Prescription Only Medicine Cryptococcosis, including Cryptococcal Meningitis and infections of other sites (e.g. Pulmonary, Cutaneous). Normal hosts and patients with acquired Immune Deficiency Syndrome (AIDS), organ transplants or other causes of Immunosuppression may be treated. Diffucan can be used as maintenance therapy to prevent relapse of Cryptococcal disease in patients with Aids. Systemic Candidiasis including Candidaemia, Disseminated Candidiasis and other forms of invasive Candidal infection. These include infections of the Peritoneum, Endocardium and Pulmonary and Urinary tracts. Candidal infections in patients with malignancy, in intensive care units, or those receiving Cytotoxic or immunosuppressive therapy may be treated. Mucosal Candidiasis. These include Oropharyngeal, Oesophageal, non-invasive Bronchopulmonary infections, Candiduria, Muco-Cutaneous and Chronic Oral Atrophic Candidiasis (denture sore mouth). Normal hosts and patients with compromised immune function may be treated. Vaginal Candidiasis, acute or recurrent. For the prevention of fungal infections in immunocompromised patients considered at risk as a consequence of neutropenia following Sytotoxic Chemotherapy or Radiotherapy. Tinea Pedis, Tinea Corporis, Tinea Cruris, Tinea Versicolor and Dermal Candida Infections. Diffucan is not indicated for nail infections.	2nd November, 1994
00109/0257	Roussel Laboratories Limited	Cefrom (250 MG I.V Injection)	Cefpirome Sulphate HSE 298 mg (Equivalent to Cefpirome Base) 250 mg	Prescription Only Medicine Bacteraemia/Septicaemia	2nd November, 1994
00173/0160	Diomed Developments Limited. T/A Dermal Laboratories	Ibuleve Spray	Ibuprofen BP 5.0% w/w	Pharmacy Medicine For the treatment of rheumatic and muscular pain, sprains, strains, backache and neuralgia.	1st November, 1994
0201/0191	Schering-Plough Limited T/A Schering-Plough Consumer Health, Division of Schering-Plough Limited	Clariteyes Eye Drops	Sodium Cromoglycate EP 2.0% w/w	Pharmacy Medicine For the treatment of Acute seasonal (Allergic) Conjunctivitis, including Hayfever.	14th November, 1994
0223/0034	Seton Healthcare Group plc	Phyllosan	Ferrous Fumarate BP 35.0 mg Nicotinic Acid EP 8.50 mg Rocoat Thiamine Mononitrate (33.33%) HSE 0.50 mg (Equivalent to Thiamine Mononitrate) USP 0.166 mg Riboflavine EP 0.333 mg Coated Ascorbic Acid SC (96%) HSE 5.20 mg (Equivalent to Ascorbic Acid) EP 5.00 mg	General Sale List Prophylaxis of deficiency states of Iron, B Vitamins and Vitamin C.	24th November, 1994
0223/0037	Seton Healthcare Group plc	Ellimans Universal Embrocation	Turpentine Oil BP 35.41% v/v Acetic Acid (80%) HSE 4.17% v/v Equivalent to Acetic Acid (33%) BP 10.37% v/v	General Sale List Symptomatic relief of muscular pain and stiffness including backache, sciatica, lumbago fibrositis and rheumatic pain and the massage by athletes of arm or leg muscles.	24th November, 1994